Announcements Trials
Browse Landscape

Phase

Phase NA 7Phase 1 4Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 10Other hematologic neoplasm 8Genitourinary 7Gastrointestinal 6Dermatologic 6Breast 6Head & Neck 5Plasma cell 4Myeloid 4CNS 4Sarcoma 3Gynecologic 3Thoracic 2Tumor-Agnostic 1Other solid neoplasm 1Other neoplasm 1Other 1Endocrine 1Classical hematology 1

Conditions

Neoplasms 1

Interventions

Gemcitabine 26Paclitaxel 24pembrolizumab 23Carboplatin 22Bevacizumab 18Radiotherapy 16Oxaliplatin 16Erlotinib Hydrochloride 16Nivolumab 15Cisplatin 14Capecitabine 14Fluorouracil 13Trastuzumab 12Docetaxel 12atezolizumab 11Magnetic Resonance Spectroscopy 11Leucovorin 11Cyclophosphamide 11Irinotecan 10Ipilimumab 10Vemurafenib 9Everolimus 9Cetuximab 9cabozantinib 8Radiosurgery 8Afatinib 8130-nm albumin-bound paclitaxel 8trametinib 7lenvatinib 7durvalumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Therapeutics × Tumor-Agnostic × Clear all
NCT03089554 2026-05-27

Evaluating Genomic Testing in Human Cancer & Outcomes of Targeted Therapies

University of Kentucky

Phase 2 Recruiting
93 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡